In conversation with... Yi-Long Wu and Caicun Zhou

from Listen to The Lancet Oncology · host The Lancet

Prof Yi-Long Wu (Guangdong Lung Cancer Institute, Guangzhou, China) and Prof Caicun Zhou (Shanghai Pulmonary Hospital, Shanghai, China) discuss the GEMSTONE 301 and GEMSTONE 302 trials on sugemalimab versus placebo in non-small-cell lung cancer.

Episode metadata supplied by the publisher feed · Published Feb 1, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

In conversation with... Yi-Long Wu and Caicun Zhou

0:00 9:56

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Oncology?

This episode is 9 minutes long.

When was this Listen to The Lancet Oncology episode published?

This episode was published on February 1, 2022.

Can I download this Listen to The Lancet Oncology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!